SonoProbe®

High Intensity Contact Ultrasound Interstitial Medical Device

Pre-Clinical Development

A preclinical evaluation program is currently in place with LabTAU, unit U1032 of INSERM in Lyon, France.

The first prototypes of MRI compatible probes were constructed and tested in animal models. They have demonstrated the effectiveness of a device capable of generating rapid tissue necrosis in brain tissue under MR guidance.

SonoProbePreClin3

With these results, more sophisticated prototypes are currently being built and tested. The encouraging results of these tests have enabled CarThera® to launch the development of probes that meet the standards required for the launch of clinical trials in humans.

 

SonoProbePreClin4

 

 

 

  • unnamed-2
    unnamed-3

     
  • News

    14.10.2016
    CarThera secures €5.7 million in funding for its DOME project

    October 12, 2016 – CarThera has received a grant of €5.7 million ($6.4m) for its DOME project. The funding was awarded under the call for proposals ‘Structuring R&D Projects for Competitiveness’ from France’s ‘Investments for the Future Program’, led by the General Investment Commission and run by Bpifrance.

    The grant will finance our SonoCloud Phase 2b/3 study in glioblastoma that will involve around 200 patients at centers in Europe and the United States. It will also fund a number of exploratory studies, including one on Alzheimer’s disease, building on the findings from the Phase 1/2a study that paved the way for a broader array of clinical indications.

    15.06.2016
    A world first published in Science Translational Medicine

    SonoCloud® uses ultrasound to achieve permeability of blood vessels in human brain, allowing increased penetration of therapeutic molecules

    Scientific paper published on June 15th 2016 in Science Translational Medicine supports concept of intracranial ultrasound implant developed by CarThera
     
    Research teams from AP-HP hospitals, UPMC University, INSERM laboratories and the ICM incubator performed this breakthrough on brain tumors, paving the way for broader applications in neurological disorders

    27.04.2016
    The Biovision 2016 Investor Conference selection committee special award went to CarThera!

    The Investor Conference of Biovision is a unique opportunity for selected startups (28 over 120 candidates) to pitch in front of a jury of 15 of the major European VC.

    Biovision, The World Life Sciences Forum, brings together international decision makers from the academic, private, policy-making and civil society sectors. It took place 13–14 April 2016 in Lyon, France.